Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Optinose (OPTN)
:OPTN
Holding OPTN?
Track your performance easily
OPTN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.82 - $31.50
Previous CloseN/A
Volume6.27K
Average Volume (3M)56.78K
Market Cap
$64.15M
Enterprise Value$161.32M
Total Cash (Recent Filing)$36.80M
Total Debt (Recent Filing)$15.26M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 06, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.23
Shares Outstanding10,055,300
10 Day Avg. Volume52,966
30 Day Avg. Volume56,782
Standard Deviation0.23
R-Squared0.00117
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.51
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda-8.39
Forecast
1Y Price Target
$12.00Price Target Upside88.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Optinose News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OPTN FAQ
What was Optinose’s price range in the past 12 months?
Optinose lowest stock price was $4.82 and its highest was $31.50 in the past 12 months.
What is Optinose’s market cap?
Optinose’s market cap is $64.15M.
When is Optinose’s upcoming earnings report date?
Optinose’s upcoming earnings report date is Mar 06, 2025 which is in 42 days.
How were Optinose’s earnings last quarter?
Optinose released its earnings results on Nov 12, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.788 by $0.788.
Is Optinose overvalued?
According to Wall Street analysts Optinose’s price is currently Undervalued.
Does Optinose pay dividends?
Optinose does not currently pay dividends.
What is Optinose’s EPS estimate?
Optinose’s EPS estimate is -0.76.
How many shares outstanding does Optinose have?
Optinose has 10,055,300 shares outstanding.
What happened to Optinose’s price movement after its last earnings report?
Optinose reported an EPS of $0 in its last earnings report, beating expectations of -$0.788. Following the earnings report the stock price went down -21.875%.
Which hedge fund is a major shareholder of Optinose?
Currently, no hedge funds are holding shares in OPTN
---
Optinose Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (88.09% Upside)
$12.00 (88.09% Upside)
Hedge Fund Trend
Decreased
By 5.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.28%
12-Months-Change
Fundamentals
Return on Equity
75.79%
Trailing 12-Months
Asset Growth
29.20%
Trailing 12-Months
Company Description
Optinose
Optinose (NASDAQ: OPTN) is a specialty pharmaceutical company focused on developing and commercializing innovative products for the treatment of diseases with significant unmet needs. The company's primary focus is on leveraging its proprietary drug delivery platform to create new therapeutic options for patients. Optinose's lead product is XHANCE, a prescription nasal spray for the treatment of nasal polyps in patients with chronic rhinosinusitis. The company operates within the healthcare and biotechnology sectors, aiming to improve patient outcomes through novel drug delivery solutions.
---
OPTN Company Deck
---
OPTN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there are positive trends in prescription growth and revenue per prescription, the overall financial performance did not meet expectations, resulting in a downward revision of revenue guidance. There are also operational challenges in prescription fulfillment and prior authorization requirements.Read More>---
OPTN Stock 12 Month Forecast
Average Price Target
$12.00
▲(88.09% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Karyopharm Therapeutics
―
scPharmaceuticals
―
Array Technologies
―
Best Analysts Covering OPTN
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-44.77%
reiterated a buy rating 2 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -44.77% per trade.
---